Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Has Erythroid-potentiating Activity
Overview
Authors
Affiliations
Tissue inhibitor of metalloproteinase (TIMP) was purified and molecularly cloned on the basis of its erythroid-potentiating activity (EPA). TIMP/EPA appears to be a bifunctional molecule with both growth factor and anti-enzymatic activity. Recently, a second TIMP-related molecule was identified and we have investigated its possible erythroid-potentiating activity. Native, purified human TIMP-2 was assayed for erythroid-potentiating activity using an in vitro erythroid burst formation assay and was compared with that of previously characterized recombinant EPA/TIMP-1. The results demonstrate that both members of the tissue inhibitor of metalloproteinase family, TIMP-1 and TIMP-2, possessed erythroid potentiating activity which was inhibited by antibodies developed to neutralize EPA. These results suggest that TIMP-2 shares a common structural domain with EPA/TIMP-1 that is responsible for the erythroid-potentiating activity of these inhibitors. Therefore, TIMP-1 and TIMP-2, with both anti-protease activity and growth factor activity, join a family of bifunctional molecules such as fibroblast growth factor and thrombin which have both enzymatic and growth factor activity.
TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer.
Zhang G, Luo X, Wang Z, Xu J, Zhang W, Chen E Aging (Albany NY). 2022; 14(1):297-315.
PMID: 35022331 PMC: 8791226. DOI: 10.18632/aging.203793.
Reflections on the evolution of the vertebrate tissue inhibitors of metalloproteinases.
Brew K FASEB J. 2018; 33(1):71-87.
PMID: 30125136 PMC: 6355094. DOI: 10.1096/fj.201801262R.
Szychowski K, Wojtowicz A, Gminski J Neurotox Res. 2018; 35(1):100-110.
PMID: 30062663 PMC: 6313372. DOI: 10.1007/s12640-018-9935-x.
Zhang X, Dai X, Wang L, Miao Y, Xu P, Liang P Front Physiol. 2018; 9:597.
PMID: 29875695 PMC: 5975577. DOI: 10.3389/fphys.2018.00597.
3D models of the hematopoietic stem cell niche under steady-state and active conditions.
Rodling L, Schwedhelm I, Kraus S, Bieback K, Hansmann J, Lee-Thedieck C Sci Rep. 2017; 7(1):4625.
PMID: 28676663 PMC: 5496931. DOI: 10.1038/s41598-017-04808-0.